The safety of regorafenib for the treatment of gastrointestinal stromal tumors.

Item

http://www.wikidata.org/entity/Q53805901

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh-hant

name

The safety of regorafenib for the treatment of gastrointestinal stromal tumors.

@en

The safety of regorafenib for the treatment of gastrointestinal stromal tumors.

@nl

type

Item

label

The safety of regorafenib for the treatment of gastrointestinal stromal tumors.

@en

The safety of regorafenib for the treatment of gastrointestinal stromal tumors.

@nl

prefLabel

The safety of regorafenib for the treatment of gastrointestinal stromal tumors.

@en

The safety of regorafenib for the treatment of gastrointestinal stromal tumors.

@nl

P1476

The safety of regorafenib for the treatment of gastrointestinal stromal tumors.

@en

P2093

Joanna Stępniak

http://www.w3.org/2001/XMLSchema#string

P2860

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapy.

Optimizing treatment outcomes with regorafenib: personalized dosing and other strategies to support patient care.

Comparison of performance of various tumour response criteria in assessment of regorafenib activity in advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib

Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial.

Towards global consensus in the treatment of gastrointestinal stromal tumor

Regorafenib as a single-agent in the treatment of patients with gastrointestinal tumors: an overview for pharmacists.

Health utility of patients with advanced gastrointestinal stromal tumors (GIST) after failure of imatinib and sunitinib: findings from GRID, a randomized, double-blind, placebo-controlled phase III study of regorafenib versus placebo.

P304

105-116

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14740338.2016.1122754

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Piotr Rutkowski

P577

2015-12-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26651387

http://www.w3.org/2001/XMLSchema#string